Cargando…
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor
Bortezomib has been successful for treatment of multiple myeloma, but not against solid tumors, and toxicities of neuropathy, thrombocytopenia and the emergence of resistance have triggered efforts to find alternative proteasome inhibitors. Bis-benzylidine piperidones such as RA190 covalently bind A...
Autores principales: | Anchoori, Ravi K., Anchoori, Vidyasagar, Lam, Brandon, Tseng, Ssu-Hsueh, Das, Samarjit, Velasquez, Fernanda Carrizo, Karanam, Balasubramanyam, Poddatoori, Deepika, Patnam, Ramesh, Rudek, Michelle A., Chang, Yung-Nien, Roden, Richard B. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266688/ https://www.ncbi.nlm.nih.gov/pubmed/37315065 http://dx.doi.org/10.1371/journal.pone.0285221 |
Ejemplares similares
-
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors
por: Anchoori, Ravi K., et al.
Publicado: (2021) -
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells
por: Soong, Ruey-Shyang, et al.
Publicado: (2016) -
Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties
por: Anchoori, Ravi K., et al.
Publicado: (2020) -
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
por: Jiang, Rosie T., et al.
Publicado: (2017) -
Covalent Rpn13-Binding Inhibitors for
the Treatment of Ovarian Cancer
por: Anchoori, Ravi K., et al.
Publicado: (2018)